NCT01274897View on ClinicalTrials.gov

A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea

PHASE3CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Meningococcal DiseaseMeningococcal Meningitis
Interventions
BIOLOGICAL

Novartis MenACWY-CRM

All subjects had blood drawn at Day 1 and Day 29.

BIOLOGICAL

Saline Placebo

All subjects had blood drawn at Day 1 and Day 29.

Trial Locations (8)

Unknown

Department of Pediatrics, Kosin University Gospel Hospital, Busan

Department of Pediatrics, Seoul National University Bundang Hospital, Gyeonggi-do

Deaprtment of Pediatrics, Inha University Hospital, Incheon

Division of Infectious Diseases, Inha University Hospital, Incheon

Pediatrics and Adolescent medicine, Myongji Hospital Kwandong University, Kyunggi

Department of Pediatrics, Ewha Womans University Mokdong Hospital, Seoul

Division of Infection Diseases, Seoul National University Hospital, Seoul

Division of Infectious Diseases, Korea University Guro Hospital, Seoul

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY

NCT01274897 - A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea | Biotech Hunter | Biotech Hunter